相关实验视频

Updated: Sep 11, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

新辅助化疗对乳腺癌免疫组织化学的作用

Jayashri Pandya¹, Shashank A Joshi¹, Harsh J Barot¹

¹General Surgery, Topiwala National Medical College & Bai Yamunabai Laxman (BYL) Nair Charitable Hospital, Mumbai, IND.

|August 11, 2025

概括

新辅助化疗 (NACT) 显著改变乳腺癌分子标记物,如雌激素受体 (ER),孕受体 (PR) 和HER2状态. 后NACT评估对于量身定制治疗和改善患者治疗结果至关重要.

科学领域:

在瘤学瘤学.
医学生物化学医学生物化学

背景情况:

新辅助化疗 (NACT) 是局部晚期或高风险早期乳腺癌的标准治疗方法.
关键的预后和预测标记包括雌激素受体 (ER),孕激素受体 (PR),HER2状态和Ki67指数.

研究的目的:

评估NACT对乳腺癌患者ER,PR,HER2和Ki67水平的影响.
评估这些分子形状变化对治疗决策的临床影响.

主要方法:

一组62名女性乳腺癌患者接受NACT.
收集基线和治疗后ER,PR,HER2和Ki67数据,通过免疫组织化学和声磁造.
使用威尔科克森等级和配对t测试进行统计分析.

主要成果:

在NACT后观察到受体状态的显著变化,包括ER (8.3%),PR (14.2%) 和HER2 (16.6%) 的负向阳性转换.
基67水平从51.7%降至26.28% (p < 0.001) 的显著下降表明瘤增殖减少.
这些变化凸显了化疗期间乳腺癌的动态性质.

结论:

NACT诱导乳腺癌分子特征的显著变化,影响受体状态和扩散标志物.
在NACT后对这些标记物的重新评估对于个性化后续治疗至关重要.
基于动态分子变化的优化治疗策略可以改善患者的长期治疗结果.

关键词:

乳腺癌患者乳腺癌患者雌激素受体 (ER) 是一种她的两个孩子.免疫组织化学 (ihc)新辅助性化疗或放射治疗.孕激素受体 (pr) 的使用

更多相关视频

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.